Aller au contenu principal

ELSALYS BIOTECH et le prestigieux institut allemand de recherche sur le cancer DKFZ initient le développement d’ELB021 dans la leucémie à cellules B avec le soutien de l’Union Européenne

  • With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation immunotherapy which acts both as immune checkpoint inhibitor and cytotoxic antibody.

  • Once validated, ELB021 should enter clinical development in 2020.


Lyon, FRANCE, 18 July 2017, ELSALYS BIOTECH, an emerging player in the field of oncology & ophthalmology, announces today that ELB021, its first-in-class monoclonal antibody targeting the cell-surface receptor CD160, has entered into a preclinical collaboration with DKFZ (the “LeukeMab Project”) under a EU-sponsored program Eurostars .

In-licensed by ELSALYS BIOTECH from Inserm Transfert in February 2016, ELB021 is a next-generation immunotherapy antibody combining complementary mechanisms of action that could improve the efficacy/toxicity cancer treatment ratio, notably in B-cell leukemias such as Chronic Lymphoid and Hairy-Cell Leukemias (CLL and HCL). Early studies have already shown that ELB021:

  • stimulates innate & adaptive anti-tumor immune response;
  • eliminates selectively cancer cells expressing CD160 (normal B cells doesn’t express  CD160 while the receptor is overexpressed in 98 % of CLL and in 100 % of HCL cells).

The overall budget amount for the LeukeMab Project is 1 million euros. Based on the promising preliminary data of ELB021, the objective is to generate the preclinical proof-of-concept and the pharmacological package that open the way to the first-in-human trial. DKFZ will provide its expertise to measure CD160 expression in CLL cells on large patients’ cohort and assess the efficacy and safety of the anti-CD160 antibody in relevant mouse models.

“The recognition by the Eurostars program underlies the therapeutic potential of our two-in-one approach in oncology. This new funding accelerates the development of this proprietary first-in-class antibodysaid Dr. Christine GUILLEN, CEO and Co-founder of ELSALYS BIOTECH. “We are also very proud to further collaborate with the DKFZ, a european leader in cancer research.”

*EUROSTARS is a European joint program co-founded from the national budgets of 34 EUREKA countries.



S'inscrire à la newsletter

Copyright 2021 ElsaLys Biotech SA

twitter    linkedin

Ce site utilise des cookies pour mesurer son audience et nous permettre d’améliorer votre expérience utilisateur.

En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de ces cookies.